AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.060
0.00 (0.00%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.

The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.

It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform.

It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases.

The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.
AN2 Therapeutics logo
CountryUnited States
Founded2017
IPO DateMar 25, 2022
IndustryBiotechnology
SectorHealthcare
Employees22
CEOEric Easom

Contact Details

Address:
1800 El Camino Real, Suite D
Menlo Park, California 94027
United States
Phone650 331 9090
Websitean2therapeutics.com

Stock Details

Ticker SymbolANTX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001880438
CUSIP Number037326105
ISIN NumberUS0373261058
Employer ID82-0606654
SIC Code2834

Key Executives

NamePosition
Eric E. EasomCo-Founder, Chief Executive Officer, President and Chairman of the Board
Joseph S. ZakrzewskiCo-Founder and Independent Chairman of the Board
Lucy O. Day CPAChief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Joshua M. Eizen J.D.Chief Legal Officer, Chief Operating Officer and Corporate Secretary
Dr. George Harrison Talbot FACP, M.D.Co-Founder and Senior Clinical Advisor
Dr. Michael R. K. Alley Ph.D.Co-Founder, Senior Vice President of Research Fellow and Head of Biology
Dr. Sanjay Chanda Ph.D.Chief Development Officer
Dr. Stephen David Prior Ph.D.Chief Strategy Officer
Vince HernandezSenior Vice President of Research and Head of Chemistry

Latest SEC Filings

DateTypeTitle
Jun 20, 20258-KCurrent Report
Jun 18, 2025SCHEDULE 13D/AFiling
Jun 11, 20258-KCurrent Report
Jun 4, 2025SCHEDULE 13GFiling
May 30, 2025SCHEDULE 13D/AFiling
May 27, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
May 7, 2025SCHEDULE 13DFiling
May 1, 20258-KCurrent Report